此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

基于 DBS 成像与基于阈值评估的编程 (DBS-ITAP)

2026年11月6日 更新者:Rob M.A. de Bie、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

比较基于成像的编程与基于阈值评估的帕金森病脑深部刺激编程的随机对照试验

The goal of this single-center prospective, randomized, open-label clinical trial is to compare the effectiveness of imaging-based DBS programming with threshold assessment-based DBS programming in patients with Parkinson's disease and motor response fluctuations.

The main question the study aims to answer is:

Is the improvement of motor symptoms in the OFF-drug phase following STN DBS for Parkinson's disease, using imaging-based DBS programming only, non-inferior to the improvement of motor symptoms following DBS programming with threshold assessment at six months follow-up?

Participants will be randomized to imaging-based programming or to threshold assessment-based programming. The main clinical outcome is motor symptoms; secondary outcomes are level of physical disability and quality of life, among others.

研究概览

详细说明

Rationale:

Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for disabling motor symptoms of Parkinson's disease (PD). Correct programming of DBS settings to provide optimal stimulation within the target region is crucial for a successful clinical outcome. To date, programming DBS settings is based on the selection of contact point(s) and stimulation parameters with standardized threshold assessments: for each contact point the current is increased in small steps and the severity of motor symptoms and possible adverse effects are assessed with each step. This process is challenging and time consuming because of the vast number of possible parameter combinations. Furthermore, individual variation in patient anatomy, placement of DBS leads and the occurrence of adverse effects must be considered. This results in long programming sessions that can be exhausting for patients and often leads to inconclusive results due to fatigue. Imaging techniques have been improved greatly over the years and could be useful for programming of DBS settings based on patient-specific anatomy.

Objective:

The aim of this study is to determine whether imaging-based DBS programming for the treatment of Parkinson's motor symptoms in STN DBS is non-inferior to the current standard practice of clinical threshold assessment-based DBS programming.

Study design:

The study is a single-center prospective, randomized, open-label, blinded end-point (PROBE design) clinical trial. Following surgery for DBS implantation, in total 132 patients will be randomized in a 1:1 ratio to initial imaging-based DBS programming (Imaging group) or to DBS programming based on initial threshold assessment (Threshold group). Follow-up is six months and consists of 3 study visits.

Study population:

Patients are eligible for the trial if they will have bilateral STN DBS for Parkinson motor symptoms at Amsterdam UMC.

Interventions:

In both groups (i.e., Imaging and Threshold), DBS programming will start two to three weeks after DBS surgery. For the DBS programming patients are admitted in the hospital for a day while they are off Parkinson medication.

Imaging group:

With the use imaging investigators are capable to visualize the location of the DBS lead within the individual's segmented anatomy and volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function), this may have the potential to improve programming of the stimulation parameters and outcomes. For this, the postoperative CT-scan is used to localize the DBS leads and the surrounding anatomic structures are reconstructed with the patient's preoperative MRI scan. Based on the patient-specific anatomy the DBS settings (appropriate contacts, amplitude, and pulse width) can be determined that produce the ideal VTA within the target and minimalizing stimulation of the surrounding structures. These settings can then be used as starting point for the programming of the stimulation parameters.

Threshold group:

Each DBS-electrode has four to 16 contact points, close to the tip, from where electrical current can be emitted. When programming DBS, the contact point or combination of contact points used for stimulation and the optimal electrical stimulation parameters are chosen. Two to three weeks after the surgery the clinician turns on the DBS. For this purpose, the patient is admitted to the hospital, and the initial threshold assessment is performed for each contact point. A crucial step in this process is to determine for each separate contact point, the amount of current needed to generate symptomatic improvement and the amount of current that generates adverse effects. To determine these thresholds, current is increased with 0.5 milliampere (mA) steps from 0 to approximately 5.0 mA, sequentially for each contact point, and the severity of Parkinson symptoms and possible adverse effects are assessed with each step. For this threshold-assessment, patients have to be off Parkinson medication (OFF-drug phase). Based on the threshold-assessments the active contact point(s) and stimulation parameters are selected. The DBS current is usually gradually increased over weeks to months with corresponding adjustments of the pharmacological treatment. For patients with bilateral DBS and four contact points on each electrode, the threshold-assessment takes about three hours.

The patient has a 50% chance of being randomized to initial imaging-based DBS programming (i.e., Imaging group). The expected benefit for this group is that they will not need the threshold-assessment and therefore have less burden due to less hospital visits for the programming. There are no extra risks associated with participation in this study. If the stimulation parameters found with imaging-based programming only do not yield enough effect in the Imaging group, the healthcare professionals can choose to execute the threshold-assessment for these patients.

Impact:

The results of the study may well contribute to reducing the burden of DBS treatment. If imaging-based programming is non-inferior to threshold assessment-based programming, this may result in more efficient programming sessions with reduced programming time (less use of health-care resources) and less discomfort for patients.

研究类型

介入性

注册 (实际的)

132

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • North Holland
      • Amsterdam、North Holland、荷兰、1105 AZ
        • Amsterdam UMC location AMC

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Parkinson's disease diagnosis based on the clinical diagnostic criteria of Movement Disorder Society
  • Scheduled for DBS screening
  • Age of 18 years or older
  • Understand the Dutch language

Exclusion Criteria:

  • Legally incompetent adults
  • No written informed consent
  • Previous functional stereotactic neurosurgery
  • Dementia
  • Current depression or psychosis

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Imaging-based

66 patients with Parkinson's disease will receive imaging-based DBS programming

Preferred contact point(s) and settings for DBS programming will be determined based on the visualization of the electrodes in the patient-specific anatomy and the volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function). This will be determined with help of the software program Brainlab with the GUIDE XT module.

有源比较器:Threshold assessment-based

66 patients with Parkinson's disease will receive DBS programming based on the threshold assessment

The preferred contact point(s) and settings for DBS programming will be determined according to current clinical practice. During the threshold assessment, the amount of electrical current needed to generate symptomatic improvement and the amount of electrical current needed to generate adverse-effects are determined for every contact point of both DBS leads by increasing current with 0.5 mA steps from 0 to approximately 5.0 mA. With each step, severity of Parkinson symptoms and presence of possible adverse-effects are assessed. For each side (i.e., left and right), the contact point with the most favorable trade-off between clinical improvement and adverse effects will be used for stimulation.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III in OFF phase
大体时间:Change from baseline to 6 months of DBS.

The MDS-UPDRS III measures severity of Parkinson's disease. The scores range between 0 - 132, higher scores indicating worse motor symptoms.

Change from baseline to 6 months of DBS.

次要结果测量

结果测量
措施说明
大体时间
MDS-UPDRS III in ON phase
大体时间:Change from baseline to 6 months of DBS.

The MDS-UPDRS III measures severity of Parkinson's disease. The scores range between 0 - 132, higher scores indicating worse motor symptoms.

Change from baseline to 6 months of DBS.
MDS-UPDRS IV
大体时间:Change from baseline to 6 months of DBS.

Part IV of the MDS-UPDRS evaluates two motor complications: dyskinesia duration and severity and motor fluctuations by means of six questions administered by a healthcare professional. The fourth part ranges from 0 to 24, with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
MDS-UPDRS I
大体时间:Change from baseline to 6 months of DBS.

Part I of the MDS-UPDRS evaluates the non-motor impact on patients' experiences of daily living by means of questions administered by a healthcare professional and self-administered questions. The first part ranges from 0 to 52, with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
MDS-UPDRS II in ON phase
大体时间:Change from baseline to 6 months of DBS.

Part II of the MDS-UPDRS evaluates motor experiences in daily living by means of a self-administered questionnaire. The second part ranges from 0 to 52 with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
Academic Medical Center Linear Disability Score (ALDS)
大体时间:Change from baseline to 6 months of DBS.

The ALDS measures the disability status of patients with a broad range of diseases. It is expressed by the ability to perform activities in daily living and each item is scored separately. The scores range between 0 - 100, lower scores indicating more disability.

Change from baseline to 6 months of DBS.
Parkinson's Disease Questionnaire 39 (PDQ-39)
大体时间:Change from baseline to 6 months of DBS.

The PDQ-39 evaluates the quality of life by means of a questionnaire containing 39 items and eight dimensions (i.e., mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort). The total score is the sum of the eight different dimensions and yields a score between 0 and 100. A higher score indicates less quality of life.

Change from baseline to 6 months of DBS.
Patient satisfaction of the outcome of treatment
大体时间:At 6 months of DBS

The degree of satisfaction scored by the patient on a 5-point Likert scale, with higher scores indicating higher experienced satisfaction.

At 6 months of DBS
Patient evaluation of the burden of therapy
大体时间:At 6 months of DBS

The degree of experienced burden scored by the patient on a 5-point Likert scale, with higher scores indicating higher experienced burden.

At 6 months of DBS
Adverse effects
大体时间:At 6 months of DBS

Number and sort of adverse effects observed during six months follow-up after DBS.

At 6 months of DBS
Use of care
大体时间:At 6 months of DBS

Total contact moments (via telephone or in hospital) during six months follow-up after DBS.

At 6 months of DBS
Total duration of programming sessions
大体时间:At 6 months of DBS

Combined duration of programming sessions during the follow-up period after DBS.

At 6 months of DBS
Final DBS settings
大体时间:At 6 months of DBS

Final stimulation parameters at 6 months after follow-up.

At 6 months of DBS

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Rob de Bie, Prof、Amsterdam UMC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年1月3日

初级完成 (实际的)

2026年10月19日

研究完成 (实际的)

2026年10月19日

研究注册日期

首次提交

2024年1月2日

首先提交符合 QC 标准的

2024年1月23日

首次发布 (实际的)

2024年1月25日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All individual participant data that underlie results in the publication will be made available

IPD 共享时间框架

It will be made available one year after the last study visit of the last participant

IPD 共享访问标准

Upon request

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅